Results 31 to 40 of about 26,895 (263)
Endocrine Journal, 2023 Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of antidiabetic drugs. Guidelines for the proper use of SGLT2 inhibitors recommend caution regarding urinary tract infections (UTIs).
Go Anan +5 more
doaj +1 more source
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Frontiers in Endocrinology, 2018 The EMPA-REG OUTCOME study revealed that a sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, can remarkably reduce cardiovascular (CV) mortality and heart failure in patients with high-risk type 2 diabetes.
Ningning Wan +3 more
doaj +1 more source
Cardiovascular Diabetology, 2020 Background Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better pleiotropic effects of SGLT2 ...
Shih-Chieh Shao +7 more
doaj +1 more source
Benefits of SGLT2 inhibitors in arrhythmias
Frontiers in Cardiovascular Medicine, 2022 Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction. With the development of research, SGLT2 inhibitors can also reduce the risk of arrhythmias.
Jinghan Gao +6 more
openaire +3 more sources
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors [PDF]
Diabetes & Metabolism Journal, 2019 BackgroundWe investigated the predictive markers for the therapeutic efficacy and the best combination of sodium-glucose co-transporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and ipragliflozin) therapy in patients with type 2 diabetes ...
Ji-Yeon Lee +7 more
doaj +1 more source
Lipids in Health and Disease, 2017 Background Previous studies suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors have different effects on the lipid profile in patients with type 2 diabetes.
Seon-Ah Cha +7 more
doaj +1 more source
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Cardiovascular Diabetology, 2020 Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF).
Atsushi Tanaka, Koichi Node
doaj +1 more source
Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
Endocrine Connections, 2020 Background and Aims: It is currently unclear whether sodium–glucose co-transporter 2 (SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce plasma glucose concentrations in humans during the early phase of ...
Yuka Goto +11 more
doaj +1 more source
Scientific Reports, 2023 The renal protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors and renin-angiotensin system (RAS) inhibitors on diabetic nephropathy without albuminuria have not been fully investigated.
Tatsuya Ishibashi +4 more
doaj +1 more source
Cardiovascular Diabetology, 2023 Recent type 2 diabetes guidance from the UK’s National Institute for Health and Care Excellence (NICE) proposes offering SGLT2-inhibitor therapy to people with established atherosclerotic cardiovascular disease (ASCVD) or heart failure, and considering ...
Katherine G. Young +6 more
doaj +1 more source